Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling studyCost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study, Published online: 20 August 2018; doi:10.1038/s41391-018-0076-3Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research